Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

Cephalon

Cephalon accepts Teva’s $6.8 billion white knight bid

May 3, 2011 Research and Development, Sales and Marketing Cephalon, Teva, Valeant, generics

Generics giant Teva has acquired Cephalon for $6.8 billion and says the deal will make it a leading specialty pharmaceutical …
News
Boehringer Ingelheim

Boehringer begins late-stage hep C trial

April 27, 2011 Research and Development BI 201335, Boehringer Ingelheim, hepatitis C

Boehringer Ingelheim has begun enrolling patients in North America for a phase III trial of its chronic hepatitis C virus …
News
Pfizer

Deaths reported in Pfizer arthritis trial

April 26, 2011 Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib

Four deaths have been reported in a late-stage study of Pfizer’s arthritis drug tofacitinib. Three of the deaths are thought …
News

Sten Westerberg joins BioInvent

April 26, 2011 Research and Development appointment, research and development, sales and marketing

Swedish pharma company BioInvent International has appointed Sten Westerberg to the newly-created position of vice president investor relations. Sten is …
Appointment

UCB and Amgen’s osteoporosis drug shows promise

April 21, 2011 Research and Development Amgen, UCB, osteoporosis

Amgen and UCB have announced strong results from a phase II study of their new postmenopausal osteoporosis treatment. Most existing …
News

Trevor Smith to lead Takeda in Europe

April 21, 2011 Research and Development, Sales and Marketing appointment, research and development, sales and marketing

Trevor Smith has been appointed chief executive of Takeda Pharmaceuticals Europe. Smith brings more than 30 years of pharmaceutical experience …
Appointment

Procurement pitfalls and hurdles of lab equipment for clinical trials

April 20, 2011 Research and Development clinical trials, medical equipment, mesm, procurement

 Over $78 billion is spent every year in the clinical trial market in the pursuit of bringing new drugs and …
Feature
Thought Leadership

Novavax appoints Stanley Erck chief executive

April 20, 2011 Research and Development appointment, research and development

US biopharmaceutical company Novavax has reorganised its senior management. The changes see former executive chairman Stanley Erck take on the …
Appointment

Warner Chilcott plans to axe 500 jobs in Europe

April 20, 2011 Manufacturing and Production, Research and Development, Sales and Marketing Warner Chilcott, pharma job cuts

Warner Chilcott is looking to cut 500 jobs from its European operations as it seeks to minimise the impact of …
News

Contract research news in brief

April 20, 2011 Research and Development CRO, contract research

Our contract research news round-up features updates from BioClinica, Vyteris, CROMSOURCE, Quintiles, Imperial/D. Anderson and PRA International. Clinical trial management …
News

Circassia raises funds to develop allergy products

April 19, 2011 Research and Development Circassia, UK biotech, biotech

UK biopharma company Circassia has raised £60 million funding for the final stage of development of its anti-allergy products. The …
News
Pfizer

Phase III boost for Pfizer’s oral arthritis drug

April 18, 2011 Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib

Pfizer’s rheumatoid arthritis treatment tofacitinib has induced clinical remission of the disease according to one-year data from a phase III …
News
Genzyme's headquarters

Genzyme MS drug shines in head-to-head trial with Rebif

April 18, 2011 Research and Development, Sales and Marketing Genzyme, Lemtrada, Sanofi-Aventis, relapsing multiple sclerosis

Genzyme’s multiple sclerosis candidate Lemtrada has impressed in a new phase II head-to-head trial. Five years’ worth of mid-stage data …
News

GlaxoSmithKline to drop Alli and other OTC products

April 15, 2011 Research and Development, Sales and Marketing Alli, GSK, OTC, Tyverb

GlaxoSmithKline is to sell off its weight loss drug Alli and other less profitable non-prescription drugs. GSK announced its decision …
News
roche

Roche growth stalls after Avastin setback

April 14, 2011 Research and Development, Sales and Marketing Roche

Revenues at Roche flattened out in the first three months of 2011, as Avastin sales declined in the US and Europe. Group …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026